Shenogen and Chemizon in cancer drug collaboration
Shenogen Pharma Group of Beijing, China and Chemizon, a division of Optomagic based in Seoul, South Korea are to collaborate on the development of small molecule therapeutics for breast cancer and osteoporosis.
Shenogen Pharma Group of Beijing, China and Chemizon, a division of Optomagic based in Seoul, South Korea are to collaborate on the development of small molecule therapeutics for breast cancer and osteoporosis.
Shenogen is developing therapeutics targeted at a novel membrane associated estrogen receptor called ER-alpha 36. The company has a pipeline of small molecule and antibody therapeutics and its lead compound for breast cancer has entered the clinical stage.
Chemizon will be responsible for a spectrum of activities for an integrated drug development programme including lead optimisation, assay development, ADME, DMPK, computational chemistry and animal pharmacology.
Financial details of the transaction were not disclosed.
"We expect the synergy resulting from this partnership will result in novel breakthrough therapies that will ultimately benefit patients afflicted with life threatening diseases," said Anthony Piscopio, chief executive of Chemizon.
Chemizon is a life sciences company focused on the discovery and development of targeted therapies to treat patients afflicted with cancer, inflammatory and metabolic diseases.
